176 related articles for article (PubMed ID: 36377082)
21. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
22. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
Hoffmann C; Welz T; Sabranski M; Kolb M; Wolf E; Stellbrink HJ; Wyen C
HIV Med; 2017 Jan; 18(1):56-63. PubMed ID: 27860104
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA;
Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329
[TBL] [Abstract][Full Text] [Related]
25. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
[TBL] [Abstract][Full Text] [Related]
26. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
27. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
28. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
[TBL] [Abstract][Full Text] [Related]
29. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
30. Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.
Kuroishi N; Watananbe A; Sakuma R; Ruzicka DJ; Hara M
PLoS One; 2019; 14(1):e0210384. PubMed ID: 30625208
[TBL] [Abstract][Full Text] [Related]
31. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
32. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
Abo YN; Refsum E; Mackie N; Lyall H; Tudor-Williams G; Foster C
Clin Drug Investig; 2019 Jun; 39(6):585-590. PubMed ID: 30976998
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.
Jesson J; Saint-Lary L; Revegue MHDT; O'Rourke J; Townsend CL; Renaud F; Penazzato M; Leroy V
Lancet Child Adolesc Health; 2022 Oct; 6(10):692-704. PubMed ID: 36058225
[TBL] [Abstract][Full Text] [Related]
34. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
35. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
37. Integrase inhibitors in children and adolescents: clinical use and resistance.
Torres-Fernandez D; Jiménez de Ory S; Fortuny C; Sainz T; Falcón D; Bernal E; Jiménez MC; Vilasaró MN; Epalza C; Navarro M; Ramos JT; Holguín Á; Prieto L;
J Antimicrob Chemother; 2022 Sep; 77(10):2784-2792. PubMed ID: 35971971
[TBL] [Abstract][Full Text] [Related]
38. Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
Kherabi Y; de Castro N; Sellier PO; Hamet G; Brun A; Méchaï F; Joly V; Yazdanpanah Y; Molina JM
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):85-90. PubMed ID: 35616997
[TBL] [Abstract][Full Text] [Related]
39. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
